Home › Companies › GHRS

GH Research

Market cap $1.25B 68.7M shares (vendor count, Nov 18, 2026) × $18.27 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2026-03-15

Pipeline (4 active programs)

Capital (as filed)

Cash
$246M cash and cash equivalents · Dec 31, 2025 (20-F)
Operating cash flow
−$10.9M annual ÷ 4, year to Dec 31, 2025 (20-F)
As stated in coverage
$351M cash per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on GH Research, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Buy speculative GH Research (GHRS): Scientific Deep Dive for GH001 Asymmetric risk/reward with massive cash protection, scalable 11-minute psychedelic treatment, and historic Phase 2b efficacy data following FDA hold lift.
  2. Hold UPDATE: GH Research (GHRS) - Q4/FY25 Update Core thesis intact with fortress balance sheet, but PK bridging study for new inhaler introduces execution risk and warrants a patient waiting game before Phase 3.
  3. Buy core UPDATE: GH Research (GHRS) - Peer-Reviewed Receipts: GH001 Defies the STAR*D Paradigm JAMA Psychiatry publication validates Phase 2b efficacy as scientific canon, and severity-independent remission rates upgrade scientific conviction to very high ahead of Phase 3.
  4. Hold UPDATE: GH Research (GHRS) - The White House Tailwind and a 54% Rip Thesis intact and strengthened by White House EO tailwind, but a 54% non-data rip elevates valuation risk and warrants trimming partial position while keeping core exposure.
  5. Hold UPDATE: GH Research (GHRS) - The Fortress Just Got Bigger (And They Used the Rip to Build It) Clean $117.5M raise led by Lynx1 at tight discount reinforces fortress balance sheet and fully funds Phase 3, with $18 as a credible re-engagement level for those who trimmed.
  6. Hold UPDATE: GH Research (GHRS) - The Bridging Gate Just Cleared (And a $200M ATM Joins the Party) Bridging study enrollment complete and Phase 3 doses selected removes the key execution gate, though new $200M ATM adds dilution overhang warranting patience around FDA Type B meeting.
  7. Buy core UPDATE: GH Research (GHRS) - The PPD Receipts Land (and They're Loud) JCP publication of PPD Phase 2a data with 100% remission and breastfeeding-compatible PK validates pipeline franchise narrative and strengthens M&A appeal alongside intact TRD thesis.
  8. Buy core UPDATE: GH Research (GHRS) - The Factory Passed Inspection FDA confirmed CMC and device plans appear Phase 3 ready, US patent granted to 2043, and European patent survived opposition, retiring the key execution and IP risks that kept conviction capped.
  9. Buy core UPDATE: GH Research (GHRS) - Three Doses Become One, and 2026 Becomes 2027 Phase 3 slips to post-Q1 2027 EoP2 meeting but device de-risked to single dose, trial design strengthened with blinded raters, Spravato veteran hired as CDO, and price reset near Lynx1's $18 entry.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (24)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 14, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

11 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)